SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing a sharp stock decline, sparking widespread investor confusion despite recent financial reports indicating better-than-expected performance. The immediate catalyst appears to be market apprehension regarding the debt impact of its substantial acquisition ambitions and a temporary halt in share buybacks. This has divided the community, with many seizing what they call a 'generational' buying opportunity, while others foresee deeper corrections due to perceived growth moderation and sector competition.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to CEO Diane Garrett's recent FoxTV interview, continuous share accumulation by billionaire investor Eric Sprott, and promising high-grade silver drill results, all against a backdrop of surging silver prices. The community is actively discussing massive upside potential and a potential short squeeze, fueled by Sprott's buying and the company's vast untapped resources. Conversely, a vocal skeptical faction highlights the lack of active mining, dilution risks, and perceived overvaluation, warning of an eventual market correction.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals (CRVS) is trending following its announcement of strong Phase 1 clinical trial data for soquelitinib in atopic dermatitis, showcasing high efficacy and a favorable safety profile that excites investors about its blockbuster potential. While the positive results have fueled significant bullish sentiment and speculation around partnerships, a recently announced public offering has simultaneously introduced dilution concerns, leading to mixed community perspectives.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing a sharp downturn as natural gas prices surge due to "mega bullish" cold weather forecasts and an anticipated "short squeeze" in long natural gas positions. The community is actively debating whether to buy KOLD on its significant dip, anticipating a potential reversal in what many perceive as overbought natural gas. Traders are navigating extreme volatility and the inherent decay of these leveraged ETFs, closely watching for further shifts in weather patterns and market sentiment for this "widowmaker" commodity.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as escalating geopolitical tensions, particularly surrounding potential US tariffs on European countries over Greenland, drive a significant 'risk-off' rotation in the markets. The community is actively discussing gold as a premier safe-haven asset, anticipating continued strong upside as investors seek protection against market instability and potential fiat currency debasement. This robust demand is pushing the metal to new highs amidst broader concerns over the US dollar and global economic conditions.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amid significant business developments, including an expanded multi-year, multi-hundred-million-dollar deal with HD Hyundai and prominent features at Davos showcasing its AI platform's efficiency. Community discussion is polarized between excitement over its AI-driven revenue growth and skepticism concerning its high valuation, alongside recent controversial reports about its work with government agencies like ICE. The company's unique position at the intersection of AI, government, and enterprise continues to fuel intense debate on its ethical implications and future growth trajectory.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending following positive FDA guidance requiring no new trials for its ANKTIVA sBLA, with resubmission expected within 30 days, signaling a clear path for label expansion in bladder cancer. The community is highly optimistic about this de-risked pathway, alongside significant international approvals like Saudi Arabia's for NSCLC, fueling strong discussions of a potential short squeeze and the company's broader impact on cancer treatment.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is a trending topic as anticipation grows for its potential PMDA approval in Japan and its presentation at the J.P. Morgan Healthcare Conference, driving significant community discussion. Investors are actively highlighting the company's innovative Alpha DaRT technology and recent strong clinical data in pancreatic cancer, signaling a potential shift towards increased institutional interest in this transformative oncology player.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is trending due to significant market volatility driven by conflicting statements from Trump regarding defense contractor operations, initially threatening buybacks but later proposing a massive defense budget increase. This, combined with ongoing global geopolitical tensions and recent strong earnings, has fueled renewed bullish sentiment and sector strength.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant volatility and trending discussions, primarily driven by expectations surrounding the potential closure of the TikTok U.S. deal and recent news of a bondholder lawsuit related to AI infrastructure debt. The community is sharply divided, with bulls pointing to the company's substantial cloud backlog and long-term AI growth prospects, while bears voice strong concerns over increasing debt levels and broader AI sector sustainability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday...

Tonix Pharmaceuticals (NASDAQ:TNXP) Cut to "Sell" at Wall Street Zen

Wall Street Zen downgraded Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

<ul class="summary-bullets"><li>Tonix intends to advance TNX-4800 with the goal of submitting an application to the FDA seeking approval to market it.</li><li>The company licensed TNX-4800 from its developers at UMass Chan Medical School in September.</li><li>There are currently no FDA-approved vaccines or preventive medicines to protect against Lyme disease.</li></ul>Tonix Pharmaceuticals Holding Corp. (TNXP) announced on Monday that it intends to meet with the U.S. Food and Drug Administration in 2026 to discuss the development of its experimental drug in the treatment of Lyme disease.The company licensed TNX-4800 from its developers at UMass Chan Medical School in September. It is being developed for annual seasonal use, as one subcutaneous administration in the spring to protect against Lyme disease through fall, or the entire tick season in the U.S., without relying on the recipient’s immune system to generate antibodies.<h2 class="st-heading-2">What Is Lyme Disease?</h2>Lyme disease is a bacterial infection caused by the bacterium Borrelia burgdorferi and spread by infected blacklegged ticks. It causes symptoms such as a bull's-eye rash, fever, fatigue, and headaches, and, if untreated, can spread to joints, heart, and brain.There are currently no FDA-approved vaccines or preventive medicines to protect against Lyme disease. According to Tonix, it is the most common vector-borne infection in the United States, and its incidence is climbing each year.<h2 class="st-heading-2">Tonix Eyes Advancing The Drug</h2>Tonix intends to advance TNX-4800 with the goal of submitting an application to the FDA seeking approval to market it.“We believe a controlled human infection model (CHIM)3-5 study using Borrelia-infected ticks that mimics natural infection would be a potential path to demonstrating TNX-4800 efficacy for approval,” <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1606/tonix-pharmaceuticals-announces-program-updates-on-phase">said</a> CEO Seth Lederman. He added that the firm expects to have the investigational product ready for clinical trials by early 2027.<h2 class="st-heading-2">Registered Direct Offering</h2>Separately, the company also announced the pricing of a $20.0 million registered direct offering on Monday<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1607/tonix-pharmaceuticals-announces-pricing-of-20-0-million"> at about</a> $16.26 per share/warrant. &nbsp;The firm intends to use the net proceeds from the offering to fund the commercialization of its marketed products, the development of its product pipeline, and general working capital and corporate purposes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TNXP stayed within the ‘bearish’ territory while message volume stayed at ‘low’ levels.A Stocktwits user sounded optimistic about the stock.<stembedurl>https://www.stocktwits.com/ZenofWealth/message/640294827</stembedurl><a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> is down 51% this year and by about 55% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nasa-administrator-jared-isaacman-sees-us-return-to-moon-before-trump-presidential-term-expiry/cLeCD4iREDB">NASA Administrator Jared Isaacman Sees US Return To Moon Before Trump’s Presidential Term Expiry</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug

The company also announced the pricing of a $20 million registered direct offering. 

Equity

The company also announced the pricing of a $20 million registered direct offering. 


Noble Financial Has Positive Outlook of TNXP FY2025 Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Investment analysts at Noble Financial raised their FY2025 earnings per share estimates for shares of Tonix Pharmaceuticals in a...

Equities Analysts Offer Predictions for TNXP FY2025 Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Equities research analysts at Zacks Small Cap raised their FY2025 earnings per share estimates for Tonix Pharmaceuticals in a report...

<ul class="summary-bullets"><li>Retail traders pointed to the expanded buyback authorization as a sign of management confidence, framing it as a potential catalyst for renewed valuation upside.</li><li>The commercial rollout of Tonmya and buyback progress strengthened bullish sentiment around the company’s turnaround.</li><li>Some users speculated that the larger repurchase program could pressure short sellers or even hint at early buyout interest.</li></ul>Tonix Pharmaceuticals stock moved into sharp retail focus on Tuesday after the company expanded its share repurchase authorization by an additional $25 million, bringing the total buyback capacity to $35 million. The move came just one day after Tonix launched Tonmya, its newly approved fibromyalgia treatment, into U.S. pharmacies.<h2 class="st-heading-2">Buyback Expansion Sparks Bullish Retail Reaction</h2>On Stocktwits, retail sentiment for Tonix was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:970/148;" src="https://news.stocktwits-cdn.com/tnxp_ss_png_226c90b15a.webp" alt="tnxp ss.png" width="970" height="148"><figcaption>TNXP sentiment and message volume as of November 18 | Source: Stocktwits</figcaption></figure>In an 8-K filing on Tuesday, the company approved the increased buyback authorization, a signal retail traders interpreted as management showing confidence in Tonix’s valuation. One user said the upbeat tone of the filing, combined with clear progress on the Tonmya rollout, created a “blueprint for a rerating,” adding that companies don’t authorize larger repurchases unless they believe the stock is undervalued.<stembedurl>https://stocktwits.com/Doyoubelieveit/message/636681899</stembedurl>Another user highlighted Tonix’s turnaround, noting that investors who bought shares before FDA approval and commercialization were taking on significantly more risk. “we now have a FDA approved product, more cash than MCAP, huge pipeline, commercialization, grants, fast track designation, increased share buyback and many more,” the user said.<stembedurl>https://stocktwits.com/StockJayC/message/636677513</stembedurl><h2 class="st-heading-2">Short-Squeeze And Buyout Speculation Emerges</h2>The buyback news also triggered speculation about pressure on short sellers. One retail trader suggested that repurchases could force shorts to compete for shares, saying the company’s decision signaled it was “done with ATM dilution.”&nbsp;Another argued the enlarged buyback could “equal huge short squeeze,” while a separate user linked the authorization to potential M&amp;A interest, saying a repurchase program “makes sense if you’re being contacted about a buyout.”<stembedurl>https://stocktwits.com/TrendSetter67/message/636675726</stembedurl><stembedurl>https://stocktwits.com/shockfactor/message/636675727</stembedurl><stembedurl>https://stocktwits.com/Ripcurlinvestments/message/636677437</stembedurl><h2 class="st-heading-2">Tonmya Launch Adds Momentum</h2>Tonix&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-tnxp-stock-jump-10-today/cLPlTiTREef">began commercial distribution of Tonmya&nbsp;</a>on Monday, a prescription, non-opioid bedtime tablet approved for treating fibromyalgia in adults. The company said the drug is now available in U.S. pharmacies, calling the launch a “momentous day” for the estimated 10 million Americans living with fibromyalgia.The treatment received FDA approval in August based on two Phase 3 trials involving nearly 1,000 patients, which demonstrated reductions in daily pain and improvements in sleep, fatigue and overall functioning over 14 weeks. Side effects were mostly mild, including drowsiness, dry mouth and temporary oral numbness.<a href="https://stocktwits.com/symbol/TNXP">Tonix’s stock</a> has slumped 51% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tonix Pharmaceuticals Stock Jumps Into Retail Spotlight After $25M Buyback Boost — Traders See ‘Blueprint For Rerating’

Retail traders pointed to the expanded buyback authorization as a sign of management confidence, framing it as a potential catalyst for renewed valuation upside.

<ul class="summary-bullets"><li>Tonmya’s FDA approval on Aug. 15, 2025, was based on results from two Phase 3 studies involving nearly 1,000 patients.</li><li>The most common side effects included mild mouth numbness or discomfort, altered taste, drowsiness, fatigue, dry mouth, and canker sores.</li><li>TNXP was among the top trending tickers on Stocktwits on Monday morning.</li></ul>&nbsp;Shares of Tonix Pharmaceuticals (TNXP) surged 10% on Monday after the company announced the launch of its new drug to treat Fibromyalgia.&nbsp;TNXP was among the top trending tickers on Stocktwits on Monday morning following the announcement. Tonix’s Tonmya is a prescription drug for the treatment of Fibromyalgia in adults. The company said that the non-opioid tablet, which can be taken once at bedtime, is now available in U.S. pharmacies.Fibromyalgia is a condition that causes widespread muscle and joint pain, often accompanied by fatigue. Its exact cause is unknown, but studies suggest that stress can play a role in triggering the symptoms.“The availability of Tonmya is a momentous day for Tonix, providing the estimated 10 million people living with fibromyalgia a novel treatment that has been shown to address the debilitating, core symptom of this disease, widespread pain,” said Seth Lederman, CEO of Tonix Pharmaceuticals.<h2 class="st-heading-2">Tonmya Trials</h2>Tonmya’s FDA approval on Aug. 15, 2025, was based on results from two Phase 3 studies involving nearly 1,000 patients, in which the drug showed meaningful reductions in daily pain over 14 weeks compared with placebo.A higher share of patients on Tonmya also achieved at least a 30% improvement in pain after three months. Findings from the RESILIENT Phase 3 trial highlighted improvements in symptoms, including sleep issues, fatigue, and overall patient functioning.The most common side effects included mild mouth numbness or discomfort, altered taste, drowsiness, fatigue, dry mouth, and canker sores.<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>Retail sentiment on Stocktwits remained in the ‘bullish’ territory over the past 24 hours, accompanied by ‘high’ message volumes. One Stocktwits user believes there is a potential for further upside before the market closes on Wednesday.<stembedurl>https://stocktwits.com/alecsalaur198/message/636442989</stembedurl>Another user believes the stock has long-term potential.<stembedurl>https://stocktwits.com/YourAverageStockGuy/message/636441761</stembedurl>TNXP shares have shed nearly half their value so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did TNXP Stock Jump 10% Today?

Tonix Pharmaceuticals on Monday announced the launch of its new drug to treat Fibromyalgia.

Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Quarterly Earnings Results

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) released its quarterly earnings results on Monday. The company reported ($3.59) earnings per share (EPS) for the quarter, hitting the consensus...

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) jumped 4% in the pre-market session on Monday after its drug Tonmya received the U.S. Food and Drug Administration’s (FDA) approval for the treatment of fibromyalgia in adults.Fibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts an estimated 10 million adults in the U.S., mostly women, and symptoms include chronic widespread pain and fatigue, among others.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1585/tonix-pharmaceuticals-announces-fda-approval-of">announced</a> the approval on Friday evening. Tonmya is a non-opioid, once-daily bedtime analgesic designed for rapid absorption into the bloodstream. It is also the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years, Tonix said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TNXP">Tonix</a> trended in the ‘extremely bullish’ territory over the past 24 hours, coupled with ‘extremely high’ message volume. According to Stocktwits data, retail chatter around the stock jumped 72% over the past 24 hours and by 281% over the past seven days.<figure class="image"><img style="aspect-ratio:566/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_18_at_8_26_39_AM_png_c112eeec38.webp" alt="TNXP's Sentiment Meter and Message Volume as of 8:25 a.m. ET on Aug. 18, 2025 | Source: Stocktwits" width="566" height="62"><figcaption>TNXP's Sentiment Meter and Message Volume as of 8:25 a.m. ET on Aug. 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user dismissed hopes for a massive rally, adding that ‘this is a marathon not a sprint.’<stembedurl>https://stocktwits.com/AlwaysABullNeverABear/message/625581652</stembedurl>Another user said they see significant market potential for the drug.<stembedurl>https://stocktwits.com/GeneralAdam/message/625580421</stembedurl>In two late-stage trials, Tonmya significantly reduced fibromyalgia pain compared to placebo at 14 weeks. The drug was generally well-tolerated in late-stage trials, and a greater percentage of study participants taking Tonmya experienced a clinically meaningful improvement in their pain after three months, compared to placebo. Tonmya is expected to be available for adult patients in the U.S. with fibromyalgia beginning in the fourth quarter of this year.TNXP stock is up by 56% this year and by over 15% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-slips-under-116000-while-cardano-solana-lead-altcoin-selloff/chsO7iYRdQw">Bitcoin Slips Under $116,000 While Cardano, Solana Lead Altcoin Selloff</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years, Tonix said. 

Tonix Pharmaceuticals drew heavy retail chatter on Tuesday ahead of an expected U.S. Food and Drug Administration decision on its experimental fibromyalgia treatment TNX-102 SL, due&nbsp;Friday.If approved, the drug would be the first new treatment for fibromyalgia in more than 16 years. It’s taken as two 2.8 mg tablets placed under the tongue before bed.&nbsp;<a href="https://stocktwits.com/symbol/TNXP">Tonix Pharma’s stock</a> jumped 32.9% to $14.79 on Tuesday, its best session in nearly five months, before edging up another 0.23% in after-hours trading.The centrally acting, non-opioid analgesic is designed for rapid transmucosal absorption, avoiding first-pass metabolism and reducing levels of a long half-life metabolite.The treatment earned Fast Track status from the FDA last year. In the late-stage RESILIENT trial, which enrolled 457 patients across 33 U.S. sites, those on TNX-102 SL reported a bigger drop in daily pain scores over 14 weeks compared with placebo, marking a 1.8-point reduction versus 1.2.&nbsp;It met all six secondary endpoints, and it's effective for sleep, fatigue, and general functioning. Side effects were mild, temporary, and generally limited to a tingling in the mouth or a bitter aftertaste. There were no serious drug-related adverse events.Tonix expects to roll out the treatment in the fourth quarter if it receives the green light, and stated that patents should protect U.S. sales until 2034-2035. The company is also testing the drug for other uses, including acute stress reaction, prevention of PTSD, Long COVID, alcohol use disorder, and agitation linked to Alzheimer’s disease.The rest of Tonix’s pipeline includes a Defense Department–backed study of TNX-102 SL for acute stress reaction, an anti-CD40L antibody called TNX-1500 aimed at preventing organ transplant rejection, and TNX-801, a live-virus vaccine candidate for mpox and smallpox.As of June 30, Tonix had $125.3 million in cash, plus additional funds from recent stock sales, which it stated will sustain operations through the third quarter of 2026.&nbsp;In the latest quarter, net revenue&nbsp;totaled $2 million, primarily from migraine drugs, while its net loss narrowed to $28.3 million from $78.8 million in the same period a year earlier.&nbsp;The company also launched its Move Fibro Forward campaign to raise awareness for fibromyalgia, a condition that affects millions of Americans and has long had limited treatment options.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 222% surge in 24-hour message volume, making it one of the platform’s top four trending equities.One user commented that $TNXP had delivered sixfold gains in six months, citing the second-quarter earnings beat and the upcoming FDA decision as reasons they considered it a “keeper.”<stembedurl>https://stocktwits.com/CCTVon/message/624881071</stembedurl>Another user remarked that despite past losses in the stock, the Fast Track status, lack of an advisory committee, and two strong Phase 3 results made the August 15 decision look promising.<stembedurl>https://stocktwits.com/SIRWINSALOT/message/624885454</stembedurl>Tonix Pharma’s stock has risen 81.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tonix Pharmaceuticals (TNXP) drew heavy retail chatter on Tuesday ahead of an expected U.S. Food and Drug Administration decision on its experimental fibromyalgia treatment TNX-102 SL, due Friday. (Photo credit: Getty Images)

Tonix Pharma Scores Best Day Since March On Hopes For First New Fibromyalgia Drug Approval in 16 Years; Retail’s Optimistic

The late-stage candidate TNX-102 SL has received FDA Fast Track status and has delivered positive results in two pivotal Phase 3 trials, demonstrating meaningful pain reduction.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

TNXP
Tonix Pharmaceuticals Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TNXP News

TNXPTonix Pharmaceuticals Holding Corp